Archives: Speakers

Dr. Paul Grint is the Executive Chairman of Codagenix. He was most recently CEO and a member of the board of directors of AmpliPhi Biosciences, which merged with C3J Therapeutics to form Armata Pharmaceuticals. Dr. Grint has more than two decades of experience in biologics and small-molecule research and development, including the successful approval and commercialization of products in the infectious diseases, immunology, and oncology therapeutic areas. Dr. Grint has also served in senior management roles at Cerexa, Forest Laboratories, Pfizer, IDEC Pharmaceuticals, and Schering-Plough Corporation. He is currently a board member at Codagenix, Inhibikase Therapeutics, Persephone Biosciences, CRISP QC and Synedgen.  He is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies, and holds a bachelor’s degree from St. Mary’s Hospital College, University of London and a medical degree from St. Bartholomew’s Hospital College, University of London.

Kay Olmstead co-founded a non-profit organization CARER Group which stands for Catalyzing Access to Research and Equity in Representation. The mission of CARER group is health equity for everyone, and one of their main projects is to promote clinical trial diversity.
Kay is also a founder and CEO of Nano PharmaSolutions. Dr. Olmstead has over 31 years of experience in pharmaceutical industry with drugs approved by FDA and one in Europe.
Dr. Olmstead has published more than 12 manuscripts and has 11 issued patents and 3 pending patent applications. Dr. Olmstead received Ph.D. degree in Organic Chemistry at Johns Hopkins University followed by a NIH post-doctoral fellowship at Stanford University.

Ditte Zerlang Andersen joined the Danish Medicines Agency (DKMA) in 2015 as a clinical trial assessor. She now leads strategic projects in our national and EU regulatory landscape as a senior strategy project lead. Ditte recently led the work of the EU ‘COMBINE’ project analysing the interface between clinical trials and the device and in vitro diagnostic area. Prior joining DKMA, Ditte worked 5 years in the pharmaceutical industry and have a PhD in neuroscience.

Director CMC since 2023.
Education and experience: Sebastian Bauer holds a PhD in chemistry (analytical biochemistry) at University of Constance, Germany (1995-1999). After a PostDoc (Vaccine research at Karolinska Insitute) he has been working in pharmaceutical industry for the last 22 years. Initially (2001-2011) in different positions in biologics pharmaceutical development (Biovitrum/Sobi). Later (2011-2023) in different positions (Project manager, Head of Development in a Recipharm/SHL JV and recently as PMO director)  in the CDMO industry for Recipharm.